Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Jul;14(10):759-764.
doi: 10.2217/imt-2021-0203. Epub 2022 Jun 27.

Safe use of intravesical bacillus Calmette-Guérin immunotherapy for bladder cancer during breastfeeding: a case report

Erol Barbur  1 , Tunkut Doganca  2 , Can Obek  3
Affiliations
Case Reports

Safe use of intravesical bacillus Calmette-Guérin immunotherapy for bladder cancer during breastfeeding: a case report

Erol Barbur et al. Immunotherapy. 2022 Jul.

Abstract

It is unknown whether intravesical bacillus Calmette-Guérin (BCG) is excreted in human breast milk. The US FDA advocates ceasing nursing due to potential adverse reactions. A lactating woman with bladder cancer who elected to receive intravesical immunotherapy with BCG and denied having ceased nursing her newborn is reported. A 42-year-old woman presented with macroscopic hematuria in the 36th week of her pregnancy. Imaging revealed a mass in the bladder. Cystoscopy and resection were performed after childbirth. Pathological examination revealed pT1 urothelial carcinoma. After a thorough discussion of the treatment options, the patient elected intravesical BCG. The infant received intradermal BCG vaccination 2 weeks before the treatment. As a result, the patient could breastfeed without any inadvertent sequela on herself or the baby.

Keywords: BCG; bladder cancer; breastfeeding; case reports; immunotherapy; lactation; surgical oncology; urology.

Plain language summary

Bacillus Calmette-Guérin (BCG) is tuberculosis vaccine. It contains live but attenuated tubercle bacillus. It is also used for bladder cancer treatment, where it is directly instilled into the bladder. BCG activates the local immune response within the bladder to fight cancer cells. The issue of whether BCG instillations into the bladder cause the bacillus to be excreted in breast milk in a lactating woman remains unknown. The US FDA suggests discontinuing breastfeeding when undergoing treatment with BCG due to potential adverse reactions. The authors report on a breastfeeding woman with bladder cancer who elected to receive BCG immunotherapy. The baby received a precautionary dermal BCG vaccination 2 weeks before the patient's treatment. Ultimately, she was able to complete her treatment while breastfeeding her child without any negative effects on the infant or herself. To the best of the authors' knowledge, this is the first article showing that breastfeeding may be safe during BCG treatment for bladder cancer.

PubMed Disclaimer

Publication types

LinkOut - more resources